Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers.  The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding scientists in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

Reporting into the VP and Head of Cancer Immunology and in partnership with cross functional R and D teams you will use your immuno-oncology expertise to help advance Revolution Medicines’ assets in clinical development. Responsibilities will include: 

• Identify potential novel antibody-directed combination strategies and support internal and external efforts to validate and prioritize these with preclinical proof of concept studies.

• Scientific input into clinical strategy for RVMD combination with antibody-directed therapy studies.

• Clinical to preclinical reverse translation: triage emergent I/O-related clinical observations, formulate hypotheses and test as appropriate to further inform clinical development plans and R and D in general.

• Strategic involvement in external partnering and business development efforts.

• Help manage a portfolio of research collaborations including establishment of new collaborations with clinical and academic investigators.

• Partner with the Head of Cancer Immunology to execute on our Cancer Immunology vision and grow and develop a passionate, talented and impactful team.

• Represent Revolution Medicines at external events including scientific conferences and investigator meetings.

Required Skills, Experience and Education:

• PhD. degree in immunology, cancer biology or a related discipline with demonstrable track record of excellence in tumor immunology and/or immunotherapy. 2-3 years of post-doctoral and at least 7 years of relevant industry experience in cancer drug discovery and translational research.

• Proven expertise advancing preclinical and/or clinical evaluation of antibody-directed therapies such as T cell engagers, ADCs or Bispecific.

• Excellent written and verbal communication skills.

• Demonstrated ability to multi-task, prioritize options, anticipate challenges, and execute on goals as a member of an interdisciplinary team is extremely important.

• Thrives in a collaborative team setting and is driven by a desire to be innovative in a high energy, small company environment.

Preferred Skills:

• Experience with translational research and early clinical strategy is desired.

• Strong track record of research productivity as evidenced by high-quality, impactful publications.

The expected salary range for this role is $195,000 to $245,000. An individual’s position within the range may be influenced by multiple factors, including skills and experience in a role, overall performance, individual impact and contributions, tenure, and market dynamics. Base salary is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.

Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.

Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].

#LI-Hybrid  #LI-LN1